Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2019-03-28 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-03-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a Preliminary Proxy Statement for a Special Meeting of Stockholders of Novavax, Inc. The content includes detailed information about the meeting agenda, voting instructions, record date, and the proposal to amend the Certificate of Incorporation for a reverse stock split. It is not an announcement of voting results but the solicitation of votes and information for shareholders to make informed decisions. The document is not a full annual report, earnings release, or other financial report but a proxy solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the proxy statement itself, not just an announcement or notice.
2019-03-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended December 31, 2018, and that the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3794 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and states that a report or press release is attached or published, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS).
2019-03-19 English
FORM 10-K
Annual Report FY 2018
2019-03-18 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-12 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.